AbbVie and Samsung Bioepis resolve Humira litigation

09-04-2018

AbbVie and Samsung Bioepis resolve Humira litigation

miodrag ignjatovic / iStockphoto.com

AbbVie has secured another settlement relating to litigation over Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.


AbbVie, Samsung Bioepis, Humira, patent infringement, settlement, litigation, biosimilar

More on this story

AbbVie and Amgen settle Humira clash
29-09-2017

LSIPR